Saxagliptin Cardiovascular Safety Affirmed, But Is It Approvable...And When?
The prospects for approval of Bristol-Myers Squibb/AstraZeneca's saxagliptin by its user fee goal date of April 30 seem remote at best
The prospects for approval of Bristol-Myers Squibb/AstraZeneca's saxagliptin by its user fee goal date of April 30 seem remote at best